

# Michelle R Downes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4563509/publications.pdf>

Version: 2024-02-01

43  
papers

865  
citations

535685

17  
h-index

563245

28  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1513  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	0.4	1
2	Morphologic Pattern, Frequency, and Spatial Distribution of Lymphovascular Invasion Foci in Radical Prostatectomy Specimens. <i>International Journal of Surgical Pathology</i> , 2023, 31, 939-948.	0.4	3
3	Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression. <i>Journal of Clinical Pathology</i> , 2022, 75, 766-771.	1.0	9
4	The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes. <i>Pathology</i> , 2022, 54, 425-433.	0.3	9
5	Upregulation of IFN $\gamma$ -mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma. <i>Scientific Reports</i> , 2022, 12, 716.	1.6	3
6	Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with synchronous or metachronous metastatic disease. <i>Prostate</i> , 2022, 82, 345-351.	1.2	4
7	Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification. <i>Modern Pathology</i> , 2022, 35, 1695-1701.	2.9	5
8	Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. <i>Journal of Clinical Pathology</i> , 2021, 74, 53-57.	1.0	15
9	Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. <i>European Journal of Cancer</i> , 2021, 148, 432-439.	1.3	13
10	The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 985-993.	1.4	2
11	A proteomic investigation of isogenic radiation resistant prostate cancer cell lines. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2100037.	0.8	4
12	Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. <i>Nature Reviews Urology</i> , 2021, 18, 707-724.	1.9	25
13	Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma. <i>Pathology Research and Practice</i> , 2021, 226, 153607.	1.0	2
14	Target prostate biopsies: how best to report in synoptic format?. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	0
15	Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. <i>Histopathology</i> , 2020, 76, 191-200.	1.6	35
16	Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 535-542.	1.4	8
17	miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. <i>Cancer Letters</i> , 2020, 473, 107-117.	3.2	33
18	Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?. <i>Pathology Research and Practice</i> , 2020, 216, 153200.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. <i>Pathology Research and Practice</i> , 2020, 216, 153186.	1.0	11
20	A Practical Approach to Investigating Cross-Contaminants in the Anatomical Pathology Laboratory. <i>International Journal of Surgical Pathology</i> , 2020, 28, 700-710.	0.4	8
21	Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder. <i>Journal of Clinical Pathology</i> , 2020, 73, 519-522.	1.0	6
22	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. <i>American Journal of Pathology</i> , 2019, 189, 2046-2060.	1.9	6
23	MicroRNA-198 suppresses prostate tumorigenesis by targeting MIB1. <i>Oncology Reports</i> , 2019, 42, 1047-1056.	1.2	16
24	Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. <i>Radiology</i> , 2019, 291, 83-89.	3.6	43
25	Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome. <i>Histopathology</i> , 2019, 75, 715-722.	1.6	18
26	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , 2019, 74, 474-482.	1.6	44
27	Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder. <i>Journal of Clinical Pathology</i> , 2018, 71, 154-160.	1.0	18
28	Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis. <i>Journal of Clinical Pathology</i> , 2018, 71, 1023-1027.	1.0	11
29	Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy. <i>Histopathology</i> , 2018, 73, 732-740.	1.6	15
30	Basal-like subtype bladder tumours show a "hot" immunophenotype. <i>Histopathology</i> , 2018, 73, 748-757.	1.6	43
31	Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. <i>Human Pathology</i> , 2018, 82, 131-139.	1.1	43
32	PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1059-1066.	2.1	79
33	Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. <i>Molecular Oncology</i> , 2018, 12, 1673-1688.	2.1	11
34	Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas. <i>Pathology Research and Practice</i> , 2017, 213, 34-38.	1.0	12
35	p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. <i>Histopathology</i> , 2017, 71, 296-304.	1.6	37
36	Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?. <i>Histopathology</i> , 2017, 71, 926-933.	1.6	23

#	ARTICLE	IF	CITATIONS
37	Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of <i>CDKN2A</i> deletions in the <i>FGFR3</i> pathway. <i>Histopathology</i> , 2017, 70, 281-289.	1.6	35
38	Isolated brain metastasis from a small renal mass. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216081.	0.2	1
39	Determination of the Association Between T2-weighted MRI and Gleason Sub-pattern: A Proof of Principle Study. <i>Academic Radiology</i> , 2016, 23, 1412-1421.	1.3	19
40	Assessment of intravascular granulomas in testicular seminomas and their association with tumour relapse and dissemination. <i>Journal of Clinical Pathology</i> , 2016, 69, 47-52.	1.0	4
41	Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. <i>Histopathology</i> , 2014, 65, 228-239.	1.6	29
42	Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. <i>European Journal of Cancer</i> , 2014, 50, 1610-1616.	1.3	137
43	Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 779-786.	1.0	23